Beam Therapeutics rises after gene-editing drug shows promise in rare lung and liver disease

Shares of biotech firm Beam Therapeutics BEAM.O rise 12% to $27.01 premarket

Co says its experimental gene‑editing drug BEAM‑302 showed promising results in an early‑stage study for alpha‑1 antitrypsin deficiency, a rare inherited condition that can damage the lungs and liver

Says a single 60‑mg dose kept patients above healthy levels of a protective lung protein for up to 12 months and sharply cut a harmful mutant protein

Drug was well tolerated, with mild to moderate side effects and no serious safety issues seen in 29 patients – BEAM

Co says it plans a late‑stage study in the second half of 2026; U.S. FDA may consider accelerated approval based on biomarker data

Shares up ~12% in 2025